Analysts expect Ascentage Pharma Group International to report revenue of 132.61 M for 2026, against a range of 125.44 M to 139.77 M. The most recent reported year, 2025, came in at 83.24 M, a 14.5% beat against the 72.72 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 4.39 M | 30.72 M | 30.71 M | 135.01 M | 83.24 M | - | - | ||
| High Estimate | 6.55 M | 31.17 M | 55.47 M | 172.89 M | 76.07 M | 139.77 M | 209.98 M | ||
| Low Estimate | 5.63 M | 26.38 M | 49.48 M | 149.58 M | 69.38 M | 125.44 M | 190.62 M | ||
| Consensus Estimate | 6.09 M | 28.78 M | 52.47 M | 161.24 M | 72.72 M | 132.61 M | 200.30 M |
Analysts expect Ascentage Pharma Group International to report earnings per share of -0.91 for 2026, against a range of -0.96 to -0.86. The most recent reported year, 2025, came in at -2.02, a 53.0% miss against the -1.32 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.93 | -1.96 | -1.82 | -0.74 | -2.02 | - | - | ||
| High Estimate | -1.56 | -1.68 | -1.56 | -0.22 | -1.28 | -0.86 | -0.36 | ||
| Low Estimate | -1.84 | -1.84 | -1.90 | -0.26 | -1.36 | -0.96 | -0.44 | ||
| Consensus Estimate | -1.70 | -1.76 | -1.73 | -0.24 | -1.32 | -0.91 | -0.40 |